Roquefort Therapeutics (ROQ) H1 2025 earnings summary

Executive summary

• Announced strategic pivot from pre-clinical to clinical stage assets, highlighted by the proposed acquisition of Coiled Therapeutics, Inc., a clinical-stage oncology company with a promising Phase I asset (AO-252).

• Signed binding agreements to sell Lyramid Pty Ltd for $10.8 million and Oncogeni Ltd for up to $12 million, with the Lyramid transaction expected to close by 31 October 2025.

• Leadership changes included the resignation of the CEO and a Non-Executive Director, with Dr. Darrin Disley appointed as Interim Managing Director.

Financial highlights

• Net loss for the six months ended 30 June 2025 was £467,167, an improvement from a £591,695 loss in the prior year period.

• Cash at period end was £182,923, down from £595,662 at 30 June 2024.

• Raised £236,000 via private placement to support working capital.

• Basic and diluted loss per share was (0.33)p, compared to (0.45)p in the prior year period.

Outlook and guidance

• Focused on completing the acquisition of Coiled Therapeutics and advancing AO-252 and STAT-6 programs into clinical trials.

• Early Phase I data for AO-252 is encouraging, with plans for dose expansion in Q4 2025 and Phase III trial planning in 2026.

• Company to be renamed Coiled Therapeutics plc and seek AIM Market admission upon transaction completion.